|
Tal Kafri MD, PhD
Associate
Professor
MD/PhD Hebrew University, Jerusalem
919.843.7635
kafri@med.unc.edu
Research Interests: The development of lentivirus vectors for gene therapy, and on basic science of
HIV-1 biology.
Publications:
- Cockrell
AS, Kafri T. Gene delivery by lentivirus
vectors. Mol Biotechnol. 2007 Jul; 36
( 3 ): 184-204 . Review.
- Bahi
A, Boyer F, Kafri T, Dreyer JL. Silencing
urokinase in the ventral tegmental area in vivo induces
changes in cocaine-induced hyperlocomotion. J
Neurochem. 2006 Sep; 98 ( 5 ): 1619-31 .
- Bahi
A, Boyer F, Gumy C, Kafri T, Dreyer JL. In
vivo gene delivery of urokinase-type plasminogen activator
with regulatable lentivirus induces behavioural changes
in chronic cocaine administration. Eur
J Neurosci. 2004 Dec; 20 ( 12 ): 3473-88 .
- Logan
AC, Haas DL, Kafri T, Kohn DB. Integrated
self-inactivating lentiviral vectors produce full-length
genomic transcripts competent for encapsidation and
integration. J Virol. 2004 Aug; 78 (
16 ): 8421-36 .
- Ma
H, Kafri T. A single-LTR HIV-1 vector optimized
for functional genomics applications. Mol
Ther. 2004 Jul; 10 ( 1 ): 139-49 .
- Bahi
A, Boyer F, Kafri T, Dreyer JL. CD81-induced
behavioural changes during chronic cocaine administration:
in vivo gene delivery with regulatable lentivirus. Eur
J Neurosci. 2004 Mar; 19 ( 6 ): 1621-33 .
|